This potential radiosensitizing ability of PARP inhibition is consistent with observations made with veliparib in other brain cancers such as glioblastoma (Jue et al., 2017), and the PARP inhibitor olaparib on D283 medulloblastoma cells (Van Vuurden et al., 2011). This evidence concerns the gene PARP1 and medulloblastoma.